entertainment -WSS

entertainment

author：leisure time 2025-09-27 12:48:57 - browse：2

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

knowledge

WSS

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

How generative AI is inspiring dreams of a health data revolution

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

FDA's Woodcock to retire early next year

Weight loss drug costs may need more research, senator suggests

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

The (many) problems with a new study criticizing cancer screening

Activists slam private health insurers over coverage restrictions

Why Novartis is changing the name of its research labs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Congress must reauthorize a committee to support older Americans

In age of alternative facts, a scholarly course on calling out crap

Weighted lottery helped low

Peter Hotez and the public health issue of online harassment

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Wikipedia

AstraZeneca chief proposes a novel edit to the drug pricing bill

Childhood cancer progress stalls for Black, Hispanic kids: Report

PBM reforms clear House panel

Illumina names Agilent executive as new CEO

CRISPR pioneers react to Casgevy, first gene

Weighted lottery helped low

knowledge

focus

knowledge

hotspot